U.S. FDA Approval Of Inlexzo™ (Gemcitabine Intravesical System) Set To Transform How Certain Bladder Cancers Are Treated
ReutersSep 9, 2025 8:36 PM
Sept 9 (Reuters) - Johnson & Johnson JNJ.N:
U.S. FDA APPROVAL OF INLEXZO™ (GEMCITABINE INTRAVESICAL SYSTEM) SET TO TRANSFORM HOW CERTAIN BLADDER CANCERS ARE TREATED
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%TradingKey
17 hours ago
Oracle Q1 FY2026 Earnings: Can Cloud and AI Drive the Next Stock Rally?
TradingKey - Oracle Corporation (NYSE: ORCL) will report Q1 FY2026 results after the close on Tuesday, September 9, 2025, with the webcasted conference call scheduled for 4:00 PM CT / 5:00 PM ET, making the print a fresh read-through on enterprise cloudTradingKey
Fri, Sep 5
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
2025 Hottest US IPO Week: Klarna, Gemini, Figure Set for “Triple Launch”
TradingKey - 5 companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8, with a total expected fundraising exceeding $3 billion, making it the busiest IPO week of 2025. Investors are closely watching the debut performance of Klarna, Gemini, and Figure.TradingKey
Wed, Sep 3
Tradingkey
